Drug side effects
degarelix Side Effects
The reactions most often reported to the FDA for degarelix (also sold as Firmagon), with demographics, serious outcomes, and reporting trends.
Data updated 2026-05-15
- 4,979
- FAERS reports
Data from the FDA Adverse Event Reporting System (FAERS), 2007 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.
The most commonly reported side effects of degarelix come from 4,979 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.
This page analyzes 4,979 reports to the FDA Adverse Event Reporting System (FAERS) for degarelix (Firmagon): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.
Total Reports
4,979
Reports Mentioning Death
576
11.6% of reports — not proof the medicine caused the death
Hospitalizations
1,629
32.7% of reports
Top Indication
Prostate Cancer
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 576 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 190 |
| DISEASE PROGRESSION | 97 |
| PROSTATE CANCER | 39 |
| MALIGNANT NEOPLASM PROGRESSION | 33 |
| PROSTATE CANCER METASTATIC | 28 |
| ASTHENIA | 23 |
| FATIGUE | 21 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 19 |
| PNEUMONIA | 19 |
| MYOCARDIAL INFARCTION | 17 |
| CARDIAC ARREST | 16 |
| DYSPNOEA | 16 |
| FALL | 16 |
| PAIN | 15 |
| ANAEMIA | 14 |
| DECREASED APPETITE | 14 |
| PROSTATIC SPECIFIC ANTIGEN INCREASED | 14 |
| PYREXIA | 12 |
| CEREBROVASCULAR ACCIDENT | 11 |
Reactions in Hospitalization Reports
Top reactions in 1,629 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| FATIGUE | 109 |
| FALL | 98 |
| PYREXIA | 93 |
| ASTHENIA | 69 |
| ANAEMIA | 62 |
| ACUTE KIDNEY INJURY | 57 |
| DYSPNOEA | 57 |
| INJECTION SITE PAIN | 56 |
| CEREBROVASCULAR ACCIDENT | 55 |
| DEHYDRATION | 55 |
| MALAISE | 55 |
| ABDOMINAL PAIN | 54 |
| PAIN | 54 |
| URINARY TRACT INFECTION | 53 |
| DEATH | 49 |
| DIZZINESS | 49 |
| DIARRHOEA | 48 |
| DECREASED APPETITE | 47 |
| INJECTION SITE ERYTHEMA | 47 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 44 |
Nearby, Related Medications
What the FAERS Data Reveals About degarelix Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 4,979 voluntary reports linked to degarelix and its brand equivalents (Firmagon), spanning 2007 through 2025. Of those, 576 (11.6%) listed death as an outcome and 1,629 (32.7%) involved hospitalization. The most common indication reported alongside adverse events was Prostate Cancer.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 1% were female and 99% male; age distribution skews toward 75+, with 1,199 reports in that bracket. The single most reported reaction is fatigue with 377 submissions, followed by injection site pain and hot flush.
How to read these numbers
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.
Drugs With a Similar FAERS Report Volume
Other medications with a total FDA adverse-event report count closest to degarelix's 4,979.
Read our methodology - how this data is sourced, computed, and verified.